Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...

Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...

Medicare needs to cover non-opioid treatments instead of riskier ones. A new legislative proposal can help cover the cost.

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

Journavx, a new non-opioid pain medication, offers a safer alternative for managing acute pain while reducing the risk of ...

A new congressionally mandated report examines how opioid and benzodiazepine prescribing between 2007 and 2019 impacted ...

CenExel, a leading network of clinical research sites, proudly congratulates and announces its role in supporting Vertex Pharmaceuticals’ clinical studies that led to the FDA approval of JOURNAVX™ ...

Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.

The US FDA has approved Journavx, a new pain reliever without the risks of addiction or overdose linked to drugs like Vicodin and OxyContin.

SOUTH SAN FRANCISCO, Calif. - Vistagen Therapeutics (VTGN), a clinical-stage biopharmaceutical company with a market ...

Dr. Sanjay Gupta said Tuesday that the approval of a new non-opioid pain medication is “a pretty big deal.” “This is a pretty ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...